June 13, 2022
June 13, 2022 –
Eli Lilly has obtained FDA approval for Olumiant® (baricitinib) oral tablets to treat severe alopecia areata in adults. Olumiant is now the first FDA-approved
June 13, 2022
June 13, 2022 –
AmvuttraTM (vutrisiran) has been approved to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
June 7, 2022
June 7, 2022 –
CellCept® (mycophenolate mofetil) has received an expanded indication for use in recipients of allogenic heart, kidney, or liver transplants
June 7, 2022
June 7, 2022 –
Regeneron’s Dupixent® (dupilumab) is now indicated to treat patients at least six months of age who have moderate-to-severe atopic dermatitis that is
June 7, 2022
June 7, 2022 –
The U.S. FDA has approved an expanded indication for Sanofi’s Lantus® (insulin glargine) to improve glycemic control in adult and pediatric patients
June 6, 2022
June 6, 2022 –
Amgen’s RiabniTM (rituximab-arrx), a biosimilar for Rituxan® (rituximab – Genentech and Biogen), is now FDA approved to for use with methotrexate
June 6, 2022
June 6, 2022 –
GSK’s Priorix® (measles, mumps, and rubella vaccine, live) has gained FDA approval to provide active immunization for the prevention of measles
June 1, 2022
June 1, 2022 –
TG Therapeutics is removing Ukoniq® (umbralisib) from the U.S. market due to a potential increase in the risk of patient death.